Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,735 INR | +0.34% | +0.94% | +3.33% |
05-14 | Zydus Wellness Sees Rise in Fiscal Q4 Consolidated Net Profit | MT |
05-14 | Zydus Wellness Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Strengths
- The group's high margin levels account for strong profits.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.81 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.7 times the sales for the current fiscal year, the company turns out to be overvalued.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.33% | 1.31B | - | ||
-2.94% | 274B | A- | ||
-0.69% | 96.48B | C+ | ||
-2.14% | 43.95B | C+ | ||
+12.04% | 42.24B | B- | ||
+1.23% | 41.25B | B- | ||
+8.77% | 40B | B- | ||
-14.61% | 30.49B | B- | ||
-6.68% | 28.7B | A | ||
+14.87% | 25.55B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ZYDUSWELL Stock
- ZYDUSWELL Stock
- Ratings Zydus Wellness Limited